Market Research Report
Global Drugs for Vulvovaginal Candidiasis Market - 2020-2027
|Global Drugs for Vulvovaginal Candidiasis Market - 2020-2027|
Published: February 9, 2021
Content info: 180 Pages
Delivery time: 2 business days
Candidiasis is an infection caused by a yeast called Candida fungi, among which, the most common is Candida albicans. This fungi normally lives on the skin as well as inside the body, in places such as the throat, gut, mouth, and vagina, without causing any problems. The Candida fungi can cause infections, incase if it grows out of control or if enters into the body, such as the bloodstream or internal organs, including the kidney, brain, or heart. However, the candida infections are hardly ever serious in healthy people. In a fewer cases, it may even spread through other parts of the body if the patient's immune system is not working properly.
The global drugs for vulvovaginal candidiasis market size was worth US$ XX billion in 2019 and further predicted to reach US$ XX billion by 2027, at a CAGR of XX% during the forecast period (2020-2027).
Certain factors that are leading the market growth include the increasing prevalence of candidiasis, the increasing R&D expenditure, and untapped opportunities in the emerging markets. However, the lack of awareness regarding the vulvovaginal candidiasis in underdeveloped economies will hamper the market growth during the forecast period.
Expecetd increase in the prevalence of candidiasis
Candidemia is one of the commonly bloodstream infections in the US. The average incidence was around 9 per 100,000 people, as per the Centers for Disease Control and Prevention (CDC). The organization has further estimated that around 25,000 cases of candidemia occur in the US each year. However, as per CDC, the incidence of candidemia declined in among infants and elderly people in the US during 2009 to 2012. This decline was due to the changes in prophylaxis guidelines and enhanced infection control practices, such as catheter care and hand hygiene. Though, the incidence of candidemia is expected to slightly increase during the forecast period, backed by the rise in the awareness of symptoms associated with candidemia.
Increasing R&D expenditure and expansion of product pipeline
The market for the fungal disease treatment has led to the introduction of a number of effective and safe antifungal agents. A few of the most effective therapies available in the market includes itraconazole, terbinafine, and fluconazole. The increasing R&D spending by the pharmaceutical companies for the development of advanced product pipeline for anti-infective drugs is one of the major factors augmenting the growth of the antifungal drug industry, which in turn, is expected to escalate the drugs for vulvovaginal candidiasis market. The market players are focusing on the development of effective therapeutic agents in immunocompromised patients to cure systemic fungal infections, including candidemia.
COVID-19 Impact Analysis
A increase in the market value of drugs for vulvovaginal candidiasis is expected in 2020, backed by the rise in the prevalence of invasive candidiasis in patients dealing with COVID-19. This is due to the rise in the healthcare-associated infections (HIAs), including cloodstream infections such as candidiasis, especially in patinets that are admitted to hospitals. Therefore, the demand for drugs for vulvovaginal candidiasis increased amid the COVID-19 pandemic, which in turn, increased the sales of the drug in 2020.
Based on the drug type, the drugs for vulvovaginal candidiasis market has been classified into miconazole, clotrimazole, fluconazole, and econazole.
Miconazole segment contributed significant share to the global drugs for vulvovaginal candidiasis market in 2019
Miconazole is a synthetic imidazole antifungal drug that eases the symptoms of candidasis by killing the candida fungus. It is majorly used as an effective treatment for vaginal thrush and fungal infections in other parts of the body. It is an oral gel that is available in the market on a prescription from a doctor; however, it can also be bought in smaller packs from pharmacies, without a prescription. It acts rapidly in relieving symptoms of yeasts, dermatophytes, and gram-positive bacteria, available for topical therapy of skin infections.
Based on the formulation type, the drugs for vulvovaginal candidiasis market has been classified into topical, pecessary, and oral.
Topical lead the market throughout the forecast period
Topical segment led the overall market with a share in 2019. A topical formulation of drugs for vulvovaginal candidiasis is used for the treatment of diseases related to the vaginal yeast, which reduces vaginal itching, pain, and discharge with this condition. The topical drug is an antifungal azole, which functions by preventing the growth of the infection-causing yeast.
Based on geography, the study analyzes the drugs for vulvovaginal candidiasis market in the global market, including North America, South America, Europe, Asia-Pacific, and the Middle East & Africa.
North America leads the global market throughout the forecast period
North America dominated the global drugs for vulvovaginal candidiasis market with the largest share in terms of value and volume globally, followed by Europe and the Asia Pacific. The US dominated the North American drugs for vulvovaginal candidiasis market in 2019. The high awareness regarding the vaginal infection from candida is one of the major factor propelling the growth of the market in the region. Moreover, the key market players are headquartered in the US, such as Pfizer Inc. and Johnson & Johnson Services Inc. are further escalating the growth of the market in North America.
Moreover, Asia Pacific is expected to project the fastest growth rate in the drugs for vulvovaginal candidiasis market during the forecast period. China dominates the market, whereas India is estimated to exhibit considerable growth in the Asia Pacific drugs for vulvovaginal candidiasis market during the forecast period. The expansion of global market players in the Asia-Pacific region due to the rising prevalence of vulvovaginal candidiasis in the region are certain factors that will propel the market growth during the forecast period.
The drugs for vulvovaginal candidiasis market is highly competitive, owing to the large presence of drugs for vulvovaginal candidiasis brands. The key drugs for vulvovaginal candidiasis players include Actavis PLC, Bristol-Myers Squibb, Bayer AG, Effik SA, Cisen Pharmaceutical, Sanofi SA, Kingyork Group, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Johnson & Johnson Services Inc. The crucial players are adopting new product launches and expansion strategies for global growth in the drugs for vulvovaginal candidiasis market.
Overview: Pfizer Inc. is a research-based pharmaceutical company that is engaged in the discovery, development, and marketing of healthcare products, including vaccines and medicines. The company operates its business across two segments, namely Pfizer Essential Health (EH) and Pfizer Innovative Health (IH). The company develops and provides over 170 different vaccines and medicines to the global market.
Product Portfolio: The company's portfolio comprises fluconazole.
The global drugs for vulvovaginal candidiasis market report would provide access to an approx. 57 market data tables, 54 figures, and 262 pages.
LIST NOT EXHAUSTIVE